We read the recent report by Aguilar et al., who concluded that among patients with nosocomial peritonitis who are on continuous renal replacement therapy (CRRT), ceftolozane-tazobactam (C/T) at a dose of 3 g every 8 h is safe \[[@CR1]\]. This finding was additional information following the notion that CRRT was an independent predictor of clinical failure when C/T was administered at 1.5 g every 8 h \[[@CR2]\]. The Aguilar et al. protocol included a short infusion time, i.e., 1 h \[[@CR1]\]. Previously described extended-infusion over 4 h was found to reach above the minimal inhibitory concentration (MIC), given that beta-lactam antibiotics exhibit time-dependent antibacterial activity \[[@CR3]\]. This might prevent underdosing during CRRT \[[@CR3]\]. Besides, the C/T elimination was explained by diffusion \[[@CR1]\]. However, adsorption was not assessed. The acrylonitrile 69 Multiflow (AN-69-M) membrane, used in this study, has a lower adsorptive capacity compared with the AN69 surface-treated (AN69-ST) membrane, which is considered a highly adsorptive membrane (HAM). In a recent comparison of polysulphone versus AN-69-M for C/T extraction by CRRT in an ex vivo model \[[@CR4]\], there was no difference in adsorption. In a case report, a continuous infusion (CI) of 6 g in 24 h of C/T was used in a cystic fibrosis patient with a multidrug-resistant (MDR) *Pseudomonas aeruginosa* and augmented renal clearance to optimize time-dependent antibacterial activity \[[@CR5]\]. In this patient, therapeutic drug monitoring (TDM) confirmed adequate exposure \[[@CR5]\]. CI and TDM are two critical parameters when using C/T for patients receiving CRRT especially when MICs of bacteria like MDR *P. aeruginosa* are considered very high.
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